Sometimes, to truly understand why a modern product is designed the way it is, it is worth going back to some of the earliest peer-reviewed evidence in the field.

In 2008, a team of researchers from the Changchun Institute of Applied Chemistry of the Chinese Academy of Sciences published a study in Biomaterials that today reads almost like a classic textbook example. Precisely because of its methodological simplicity, thoroughness, and consistency, it remains worth examining closely, especially for us as a team developing ResorBone™ for 3D-printed biodrook implants.

The problem researchers were trying to solve more than 15 years ago

Poly(lactide-co-glycolide), better known as PLGA, is one of the most extensively studied resorbable polyesters in medicine, with a long history of clinical use and an established safety profile.

The problem was not its safety, but its biological “passivity.” On its own, without additional components, PLGA has no intrinsic osteogenic bioactivity. It does not actively stimulate osteoblasts to produce more new bone matrix. Instead, it mainly occupies space mechanically and gradually degrades.

Hydroxyapatite (HA), by contrast, is a structural and chemical analogue of the mineral component of natural bone. The calcium-to-phosphorus atomic ratio of the HA synthesized in this study, approximately 1.67, closely matches that of natural bone apatite.

However, raw, unmodified HA has an important drawback when used in composites: it tends to aggregate, forming clusters approximately 2–5 μm in size within the polymer matrix rather than distributing evenly across the pore surfaces of the scaffold, where the mineral is most useful for direct interaction with bone cells.

The researchers therefore proposed an elegant solution: synthesizing hydroxyapatite with poly(L-lactide) grafted onto its surface, creating a material they called g-HAP.

The idea was that a thin polymer layer would improve the compatibility of each HA particle with the surrounding PLGA matrix and prevent the formation of large aggregates. The grafted polymer accounted for approximately 5% of the particle mass, a relatively thin layer that nevertheless proved functionally meaningful in subsequent analyses.

Two independent tests: one in muscle and one in actual bone

The researchers evaluated three materials: pure PLGA, an unmodified HAP/PLGA composite, and the new g-HAP/PLGA composite.

They tested them using two parallel and complementary approaches.

The first involved intramuscular implantation in 18 rabbits, with three parallel samples of each material implanted in each animal. This model allowed the researchers to observe biodegradation and mineralization without the influence of mechanical loading or the natural bone microenvironment.

The second approach was considerably more complex and clinically relevant: reconstruction of a true critical-sized radial bone defect.

A 2 cm diaphyseal defect was surgically created in 12 rabbits. In this part of the experiment, the researchers also investigated the effect of the osteogenic factor BMP-2 by soaking g-HAP/PLGA scaffolds in a BMP-2 solution before implantation.

The implants in both parts of the study were evaluated at 4, 8, 12, and 20 weeks using a range of methods, including scanning electron microscopy, computed radiography, inductively coupled plasma atomic emission spectroscopy (ICP-AES) for precise quantitative measurement of calcium content, and conventional histology with hematoxylin and eosin and Masson’s trichrome staining.

Bone that formed like real bone

The results created a convincing picture at both levels of observation.

Following intramuscular implantation, both composite materials were substantially more stable than pure PLGA and demonstrated similar patterns of mineralization and biodegradation throughout the observation period.

Both composites showed two possible outcomes.

In some samples, extensive active mineralization occurred, accompanied by a sharp increase in calcium content, reaching as much as 18.7–19% of the material mass by week 20, almost six times the initial level.

Other samples of the same material underwent predominantly resorption.

This dual pattern appeared to depend on uncontrolled local factors in the microenvironment surrounding each individual specimen rather than solely on the chemistry of the material itself.

The more clinically relevant test, however, was the second part of the study involving true bone defects.

Here, the results were much clearer.

Hydroxyapatite-containing composites supported faster and more extensive new bone formation and demonstrated greater osteoconductivity than the pure polymer. The addition of BMP-2 to g-HAP/PLGA further accelerated this process.

By eight weeks, the calcium phosphate composite groups showed a genuinely integrated bone structure, with a clearly defined cortical layer and a fully developed medullary cavity.

In the pure PLGA group, the defect remained partially unfilled at the same time point, and bone formation occurred mainly from the peripheral periosteum rather than directly along the implant surface.

The comparison between modified and unmodified hydroxyapatite was also particularly interesting.

Surface modification of g-HAP did indeed produce a more uniform distribution of nanoparticles across the scaffold pore surfaces compared with unmodified HAP, where characteristic aggregation into 2–5 μm clusters was still observed.

However, the authors openly acknowledged an important point: despite this improvement in particle distribution, the final osteoconductivity and mineralization of the g-HAP/PLGA group were almost identical to those of the unmodified HAP/PLGA group, even though the actual hydroxyapatite content in g-HAP/PLGA was slightly lower.

This led to a practical engineering conclusion: the overall availability of calcium and phosphorus within the composite may be a key determinant of osteogenic activity, not merely the quality of particle dispersion.

An early but fundamental step toward the engineering logic behind ResorBone™

This study is one of the early and particularly illustrative examples in the scientific literature showing why combining a resorbable polyester with a calcium phosphate phase, rather than using the polymer alone, can provide osteoconductive properties in a bone implant.

In the more than 15 years since this work was published, numerous subsequent studies, including those discussed in previous articles in this series, have expanded and refined this fundamental concept across different animal models, polymer-to-mineral ratios, and manufacturing technologies, including modern 3D printing.

ResorBone™, the material used to manufacture biodrook implants by 3D printing, belongs to this broad family of polymer-mineral composites.

The 2008 study investigated a chemically related but distinct g-HAP/PLGA system developed by another research institution. It did not evaluate ResorBone™ or biodrook products.

Direct testing of biodrook products in animal models therefore remains a separate research stage, one that we regard as a logical and scientifically grounded continuation of this well-established research tradition.

Nevertheless, more than 15 years of accumulated evidence on resorbable polymer–hydroxyapatite composites, of which this study was one of the early systematic demonstrations in a true bone-healing model, provides an important scientific basis for the broader engineering approach applied in ResorBone™.

Source

Zhang P, Hong Z, Yu T, Chen X, Jing X. In vivo mineralization and osteogenesis of nanocomposite scaffold of poly(lactide-co-glycolide) and hydroxyapatite surface-grafted with poly(L-lactide). Biomaterials. 2009;30(1):58–70. doi:10.1016/j.biomaterials.2008.08.041

This article is a popular science review of a published study and does not constitute an advertising claim regarding the properties of a specific medical device. The conformity and clinical performance of biodrook implants are supported by the manufacturer’s own documentation.

A distal radius fracture, a fracture of the forearm bone close to the wrist, is statistically one of the most common fractures in the human body, accounting for approximately 8–17% of all bone fractures and up to 72% of all forearm fractures. In the United States alone, around 200,000 people sustain this injury each year. One of the most frequent and serious complications is malunion, when the bone heals in an incorrect, displaced position and disrupts the biomechanics of the entire wrist.

The standard surgical solution is a corrective osteotomy: the surgeon intentionally “re-breaks” the bone at the appropriate location and angle, then fixes it again using a titanium plate secured with screws. According to Japan’s Ministry of Health, Labour and Welfare, titanium is used in 95% of orthopedic implants and 70% of surgical implants overall.

But titanium is a compromise. It provides rigid fixation, leaving limited room for natural physiological flexibility, which may be particularly relevant in the developing skeleton. Documented, although relatively uncommon, issues include plate migration, temperature sensitivity, discomfort caused by palpable metal beneath the skin, and, in rare cases, allergic reactions. Perhaps most importantly, a second procedure is often required to remove the plate.

In a 2024 study published in 3D Printing in Medicine, a team from the University of Basel in Switzerland asked an ambitious question: could a titanium plate be replaced with a patient-specific, fully resorbable, 3D-printed wedge implant that gradually degrades after completing its mechanical function?

This question directly intersects with the broader engineering direction behind ResorBone™, the material used to 3D print biodrook implants.

A wedge instead of a plate: a different geometric philosophy

The idea behind the new approach is elegant in its simplicity.

Instead of an external plate spanning the osteotomy site on the outside of the bone, the authors designed a compact wedge-shaped patient-specific implant, or WSPSI, that is inserted directly into the osteotomy gap, much like a wedge placed into a split.

The implant is fixed exclusively with resorbable compression screws, without any external metallic plate.

The process began with CT scanning of Thiel-embalmed cadaveric forearms, segmentation of the distal radius anatomy, and virtual osteotomy planning with an exact correction angle of 35 degrees, consistent with a previously published surgical reference protocol.

The osteotomies were incomplete, intentionally leaving the volar cortical layer intact. This technique provides additional natural stability even before the implant itself is inserted.

The wedge-shaped implants were designed with a clearance of only 0.5 mm from the dorsal bone surface to minimize the risk of material protruding beyond the natural bone contour.

Each wedge was designed to accommodate a 16 mm bioresorbable compression screw with a gradually increasing diameter from 3 to 3.7 mm.

The printing material was commercial Resomer® LR 706 S, a composite consisting of 70% PLDLLA and 30% β-tricalcium phosphate. It belongs to the same broad class of materials based on a resorbable polyester combined with a calcium phosphate phase that is also relevant to the engineering concept behind ResorBone™.

The implants were manufactured using Arburg Plastic Freeforming, a technology that combines aspects of injection molding with layer-by-layer additive manufacturing.

The moment of truth: axial compression until failure

Four cadaveric forearms received the new resorbable wedge implant, while a fifth was fixed using a conventional titanium plate as a direct reference.

Each specimen was embedded in acrylic resin, mounted in a universal testing machine, and loaded axially at a rate of 1 mm per minute until structural failure occurred.

The results were encouraging.

All PLDLLA/β-TCP wedge implants withstood at least 1,211 N of axial compression before any structural damage began.

This is an important figure. Previously published biomechanical data suggest that the peak impact force transmitted to the wrist during a typical forward fall from approximately shoulder height, around one meter above the ground, is about 1,021 ± 161 N.

In other words, even the weakest tested resorbable specimen tolerated a mechanical load above that associated with a realistic and clinically relevant fall scenario during the early postoperative period.

The best-performing specimen reached a maximum force of 2,736.4 N before cortical bone failure, while the titanium plate in the reference specimen failed at 2,415.6 N.

In its strongest configuration, the resorbable composite therefore demonstrated mechanical performance comparable to, and in this isolated specimen slightly higher than, the titanium reference.

The researchers also carefully analyzed how each sample failed.

In one specimen, a crack propagated outward from the edge of the drilled screw hole. This highlighted an area requiring further engineering optimization, for example by increasing the distance between the screw hole and the edge of the implant.

A material that does not contaminate itself during manufacturing

Alongside mechanical testing, the researchers carried out a separate degradation study.

Samples were tested in real time at 37°C and under accelerated conditions at 50°C for up to four weeks. Using the Hawkins accelerated-aging relationship, this was estimated to correspond to approximately 10 weeks of degradation at normal body temperature.

The results were cautiously but consistently encouraging.

The pH of the surrounding solution remained within a physiologically acceptable range of 7.4 ± 0.2 throughout the observation period, with no sharp acidification.

EDX analysis detected no metallic particles potentially introduced from the 3D printer nozzle during manufacturing. This was an important confirmation that the production process did not contaminate the composite with foreign metallic particles, despite the ceramic β-TCP phase being harder than the metal nozzle.

Sample mass loss during accelerated degradation was very small, ranging from 0.002% after 24 hours to a maximum of 0.467% at the longest accelerated-aging time point, suggesting a slow and controlled degradation process.

The study also revealed several important practical limitations, which the authors openly acknowledged.

The measured glass transition temperature of the material was 50.26°C, substantially lower than the manufacturer’s stated specification of 60°C. The authors associated this difference with the thermal and mechanical processing involved in 3D printing, during which the material was exposed to temperatures of approximately 205°C and pressures of around 200 MPa.

This is an important reminder that the manufacturing process itself can alter the physical properties of the original raw material and therefore has to be carefully controlled and validated at every stage.

Mechanics, chemistry, and what still needs to be studied

This study provides an important signal for the broader field of 3D-printed resorbable implants.

Patient-specific implants made from resorbable polyester/β-tricalcium phosphate composites can demonstrate mechanical strength in the same general range as titanium fixation while maintaining slow, controlled degradation.

This is also relevant to the broader engineering direction behind ResorBone™.

However, the material tested in this study was specifically Resomer® LR 706 S, not ResorBone™, and the experiments were conducted using prepared cadaveric forearms rather than living patients or biodrook devices.

The authors also acknowledge an important methodological limitation: the study evaluated axial mechanical loading and material degradation, but not the biological response.

In other words, the study did not investigate how living bone would heal in direct contact with such a wedge implant. That remains an essential next research step for this entire class of devices.

Even so, the mechanical and physicochemical findings strengthen the engineering rationale for exploring resorbable calcium phosphate composites as an alternative to permanent metallic fixation in selected trauma and reconstructive applications.

This article is a popular science review of a published study and does not constitute an advertising claim regarding the properties of a specific medical device. The conformity and clinical performance of biodrook implants are supported by the manufacturer’s own documentation.

Source: Jakimiuk A, Maintz M, Müller-Gerbl M, Thieringer FM, Keller M, Guebeli A, Honigmann P. 3D-printed patient-specific implants made of polylactide (PLDLLA) and β-tricalcium phosphate (β-TCP) for corrective osteotomies of the distal radius. 3D Print Med. 2024;10:42. doi:10.1186/s41205-024-00240-z

Imagine a structure made of two materials: a flexible framework and rigid blocks placed next to each other but not truly bonded. Under load, such a structure will always begin to fail at the interface between the two phases, where they touch but do not hold onto each other. This is almost a literal metaphor for one of the main engineering challenges that developers of bone implants have been trying to solve for decades.

A resorbable polymer on its own is soft, flexible, and tissue-friendly, but biologically “silent.” It degrades well and does not cause a toxic reaction, yet it provides little signaling to bone cells to encourage them to proliferate and form new tissue. Hydroxyapatite (HA), on the other hand, is chemically and structurally similar to the mineral component of natural bone, which is why cells readily “recognize” it. But pure HA is brittle, resorbs poorly, and, most importantly for composite engineering, does not bond well with the polymer matrix at the molecular level. Mineral particles tend to aggregate into clusters rather than distribute evenly throughout the material.

This is the problem a team of materials scientists and surgeons from Nanchang University and Wuhan University in China set out to address in a 2014 PLoS ONE study of a composite with the lengthy name PBLG-g-HA/PLLA.

Behind the abbreviation lies a relatively simple idea: molecules of poly(γ-benzyl-L-glutamate), a synthetic polypeptide, are chemically “grafted” onto the surface of each hydroxyapatite nanoparticle. This creates a molecular transition layer between the mineral and the poly-L-lactide (PLLA) polymer matrix.

The principle itself is not new. Surface modification of inorganic fillers to improve compatibility with an organic matrix has been used in materials science for decades. But applying this approach to calcium phosphate bone composites became one of the building blocks of a broader field of biomaterials engineering, a field that today also includes ResorBone™, the material used to 3D print biodrook implants.

Study design: four groups, eighteen animals, three time points

The researchers used a classic bilateral femoral condyle defect model in Wistar rats, with each animal receiving two defects, one in each limb.

This allowed four treatment options to be distributed among 18 animals: an empty control defect, pure PLLA without a filler, an unmodified HA/PLLA composite, and the new PBLG-g-HA/PLLA composite.

The scaffolds were manufactured using thermally induced phase separation, a technique that produces a porous three-dimensional structure without the use of solvents whose residues could pose a risk to surrounding tissue.

At 2, 4, and 8 weeks, the animals were evaluated using a range of complementary methods.

Micro-CT provided a quantitative three-dimensional picture of how much mineralized tissue had formed as a percentage of the total defect volume, expressed as BV/TV.

Hematoxylin and eosin histological staining revealed the overall tissue architecture under a light microscope. Safranin O staining identified areas of endochondral ossification, the process of bone formation through an intermediate cartilage stage that also plays a key role in the natural development of long bones.

Immunohistochemistry for type I collagen showed how actively cells were producing the main protein framework of the bone matrix. TRAP staining was used to identify osteoclasts, the cells responsible for bone resorption, whose excessive activity could potentially indicate an inflammatory or adverse tissue response.

What happened to the bone at each stage

The micro-CT results remained consistent throughout the observation period.

By the second week, the amount of newly formed bone in the hydroxyapatite-containing groups had already begun to noticeably exceed that observed with pure PLLA. This difference continued to increase through week eight.

There was, however, an important nuance. No statistically significant difference between HA/PLLA and PBLG-g-HA/PLLA was observed at any of the evaluation points. Both mineral-containing composites produced approximately similar results, even though surface modification was theoretically expected to improve particle distribution within the matrix.

Histology added important details.

In the HA-containing groups, abundant bone formation was observed, with a substantial proportion developing through the endochondral pathway, a mechanism that closely resembles physiological bone development.

Type I collagen staining showed the highest expression in the mineral-containing groups. This indicates more than simply the presence of calcium in the tissue. It reflects active maturation of the organic bone framework into which hydroxyapatite crystals can subsequently be incorporated.

The number of osteoclasts did not differ statistically among the four groups. Neither composite triggered excessive pathological resorption, suggesting that the materials did not provoke an abnormal tissue response in this model.

What this means for composite material engineering

The main conclusion of this study extends beyond the specific PBLG molecule.

It concerns the fundamental principle behind the design of bone implants: the presence of a calcium phosphate phase within a resorbable polymer matrix, rather than the polymer alone, can support osteoconduction, the ability of a material to provide a surface or structure along which new bone can grow.

A polymer without a mineral phase essentially remains a temporary mechanical scaffold. A polymer with a properly integrated mineral phase has the potential to “communicate” with bone cells in a chemical environment that is more familiar to them.

ResorBone™ does not use the specific PBLG surface-grafting technology described in this study, and none of the studies reviewed in this series directly tested ResorBone™ or biodrook products.

However, the principle underlying PBLG-g-HA/PLLA, combining a resorbable polymer with a calcium phosphate phase to support osteoconduction, is also fundamental to the material approach used in ResorBone™.

Each new study in this field, including this one, contributes to the broader scientific foundation behind this direction in bone biomaterials engineering and helps explain the rationale behind the material strategy selected for ResorBone™.

This article is a popular science review of a published study and does not constitute an advertising claim regarding the properties of a specific medical device. The conformity and clinical performance of biodrook implants are supported by the manufacturer’s own documentation.

Source: Liao L, Yang S, Miron RJ, Wei J, Zhang Y, Zhang M. Osteogenic Properties of PBLG-g-HA/PLLA Nanocomposites. PLoS ONE. 2014;9(9):e105876. doi:10.1371/journal.pone.0105876

Most scientific studies of bone implants are limited to weeks or, at best, a few months of observation. This is understandable: animal studies are expensive, time-consuming, and require careful ethical approval. But this creates an important gap in our knowledge. What actually happens to a resorbable material one year after implantation? Or a year and a half later? Does the composite lose contact with bone over such a long period, when the polymer phase is already actively degrading but the newly formed bone has not yet reached its final architecture?

A French team led by Guy Daculsi from the University of Nantes set out to answer exactly these questions. Their publication in Biomaterials in 2011 reported an observation period of 76 weeks, almost a year and a half of continuous monitoring in a living animal model.

Three materials tested over the long term

The study compared three materials.

The first was pure P(96L/4D)LA copolymer, a polylactide containing L- and D-lactide monomers in a 96:4 ratio. The small proportion of D-lactide intentionally disrupts the highly ordered crystalline structure of pure poly-L-lactide, making the material less crystalline and allowing somewhat faster, more controlled degradation.

The second and third materials were composites based on the same polymer combined with β-tricalcium phosphate (β-TCP) at concentrations of 10% and 24%.

The materials were produced using twin extrusion followed by self-reinforcement, a process that aligns polymer molecular chains along the axis of the implant and significantly increases the mechanical strength of the final device.

Cylindrical specimens measuring 6 mm in diameter and 8 mm in length were implanted into critical defects of the lateral femoral condyle. In total, 54 cylinders were implanted in 27 rabbits, which were divided into observation groups of 24, 48, and 76 weeks.

The methodological depth of this study remains impressive even by modern standards.

The researchers used micro-CT for three-dimensional quantitative assessment, backscattered electron scanning microscopy for detailed analysis of the bone-implant interface, and polarized light microscopy with a special filter that made it possible to clearly distinguish oriented collagen in newly formed bone, soft tissue, and β-TCP particles.

One of the most sophisticated methods was fluorescent labeling of living animals using two tetracycline injections, administered 10 and 2 days before euthanasia. This effectively “highlighted” areas of active bone formation at a time point very close to the end of each observation period.

Diverging pathways: when hydrolysis becomes visible

During the first 24 weeks, all three groups behaved relatively similarly.

Hydrolysis of ester bonds within the polyester chains had only begun, and no major visible differences were observed.

Between weeks 24 and 76, however, the behavior of the three materials began to diverge significantly.

By week 76, the pure polymer group showed extensive degradation. The implant had begun releasing small particles directly into the surrounding tissue, and clear histological signs of localized resorption of the adjacent bone were observed.

In simple terms, the body had begun breaking down its own already formed peripheral bone more rapidly and less predictably than the polymer was creating controlled space for tissue replacement.

The two β-TCP-containing composites behaved very differently.

Direct bone contact did decrease somewhat over time, which is a natural consequence of material degradation. However, bone trabeculae remained attached perpendicular to the implant surface and maintained direct physical contact with calcium phosphate particles even when the surrounding polymer matrix was already undergoing substantial degradation.

At 76 weeks, bone contact with the composite containing 24% β-TCP was 64% higher than with the pure polymer.

Micro-CT also showed that three-dimensional loss of bone contact reached 54% in the pure polymer group at this time point, while it was substantially lower in both composite groups.

The most compelling evidence, however, came from fluorescent labeling.

Active bone remodeling at the implant-bone interface persisted throughout the entire observation period only in the β-TCP-containing groups.

In the pure polymer group, no active bone remodeling at the interface was detected after week 48. In the authors’ description, the interface had essentially become biologically inactive.

Buffering chemistry: why the mineral phase can reduce acidity

The mechanism can be explained by the basic chemistry of polyester degradation.

When an aliphatic polyester undergoes hydrolysis, water molecules attack the ester bonds within the polymer chains, generating carboxyl end groups and acidic degradation products, including lactic acid and related oligomers.

At sufficiently high local concentrations, these products can lower the pH of the surrounding tissue environment. This may irritate neighboring cells and contribute to increased or less predictable resorption, which is consistent with what was observed in the pure polymer group.

Calcium phosphate particles within the composite can act as an internal chemical buffer.

As they gradually release calcium- and phosphate-containing species, they can help neutralize acidic degradation products close to the site where those products are generated, reducing excessive deviation of the local pH from physiological conditions.

This provides an elegant solution to one of the fundamental challenges associated with resorbable polyester implants.

The broader principle of controlled degradation of a polymer matrix combined with an osteoconductive mineral phase is also relevant to the engineering approach behind ResorBone™, the material used to 3D print biodrook implants.

The study by Daculsi et al. investigated a specific P(96L/4D)LA/β-TCP system, not ResorBone™ or biodrook products directly. Nevertheless, it remains one of the longest and most methodologically detailed studies showing how this class of composites can behave in living bone tissue over a genuinely long healing period, not merely weeks, but many months and more than a year.

This article is a popular science review of a published study and does not constitute an advertising claim regarding the properties of a specific medical device. The conformity and clinical performance of biodrook implants are supported by the manufacturer’s own documentation.

Source: Daculsi G, Goyenvalle E, Cognet R, Aguado E, Suokas EO. Osteoconductive properties of poly(96L/4D-lactide)/beta-tricalcium phosphate in long term animal model. Biomaterials. 2011;32:3166–3177. doi:10.1016/j.biomaterials.2011.01.033

In biomaterials science, there are two fundamentally different levels of how “good” a material can be in relation to bone, and the distinction between them is easy to miss if you do not know what to look for.

The first, more familiar level is osteoconduction: the ability of a material to passively support bone growth along its surface, acting as a compatible scaffold along which cells can migrate and deposit new matrix.

The second, much rarer and potentially more clinically valuable level is osteoinduction: the ability of a material to initiate the formation of entirely new bone tissue without any added cells or growth factors, even in a location where bone would not normally form, for example, within skeletal muscle.

For a long time, the scientific literature largely considered osteoinduction to be an almost exclusive property of porous calcium phosphate ceramic materials, with internal porosity regarded as essential for this effect.

A study by a team from the University of Twente and the biotechnology company Xpand Biotechnology in the Netherlands, published in Biomatter in 2014, challenged this established assumption. Its findings are also relevant to the engineering of 3D-printed devices based on composite materials from the broader class to which ResorBone™ belongs.

The idea: a dense material with an artificially created “protected space”

The key engineering concept was to manufacture the composite by extrusion, a process that does not require organic solvents at any stage of production.

Residual solvents in a finished implant can be extremely difficult to remove completely, and even trace amounts may be harmful to surrounding tissues.

The composite consisted of 50% poly(D,L-lactide) and 50% custom-produced nanoscale hydroxyapatite, with particles approximately 309 nanometers long and 70 nanometers wide.

FTIR spectroscopy confirmed successful incorporation of the mineral phase into the polymer matrix. The composite spectrum showed clear phosphate and hydroxyl absorption bands characteristic of hydroxyapatite and absent from the spectrum of pure PLA.

The extrusion process produced a dense, completely nonporous material, essentially the opposite of the type of structure traditionally considered necessary for osteoinduction.

To determine whether such a dense material could nevertheless initiate bone formation, the researchers designed a somewhat unconventional but conceptually elegant implant.

Two dense composite plates were bonded together and separated by thin spacers. This created a narrow, artificially formed protected gap between the plates, effectively mimicking an internal pore even though the material itself remained completely nonporous.

Dogs, paravertebral muscle, and twelve weeks of observation

Twelve PLA/HA composite implants and five control implants made of pure PLA were implanted intramuscularly in eight adult mongrel dogs.

After 12 weeks, the animals were euthanized and the implants together with the surrounding tissues were collected for detailed histological analysis.

The results were already striking at the most basic stage, sample retrieval.

Of the five implanted pure PLA samples, only two could be located. At the sites where the remaining three should have been, the researchers found no detectable material or tissue reaction beyond normal muscle tissue. The polymer had apparently degraded without leaving any obvious trace.

By contrast, all twelve PLA/HA implants were successfully retrieved. Two were later excluded from histological analysis because of a technical issue during sample preparation.

The most important finding appeared under the microscope.

In all ten successfully analyzed PLA/HA samples, the researchers observed true heterotopic bone formation within muscle tissue, without the addition of cells or growth factors.

The greatest amount of bone formed near the entrance to the artificially created protected gap and in areas where degradation of the composite itself was most pronounced.

The newly formed bone had a physiological appearance, with mineralized matrix directly aligned with a layer of active osteoblasts. The maximum depth of bone ingrowth into the implant reached approximately 4 mm.

In neither of the two recovered pure PLA samples was any histological evidence of bone formation observed, despite clear signs of polymer degradation.

Cell biology supported what the animal model showed

Before the in vivo stage, the researchers also demonstrated that the PLA/HA composite steadily released calcium and phosphate ions into physiological saline throughout the entire 12-week observation period, without reaching a plateau.

Pure PLA, by contrast, released no measurable amounts of these ions over the same period.

Alkaline phosphatase, or ALP, activity in cells cultured on the composite was higher than on pure PLA in both tested media. The difference reached statistical significance on day 14 in the osteogenic culture medium.

What this means for 3D-printing geometry and architecture

The significance of this study extends beyond one specific PLA/HA composition.

It suggests that osteoinductive potential may also emerge in dense, completely nonporous composites based on a resorbable polyester combined with hydroxyapatite, provided that the overall implant design creates the right geometric conditions.

One particularly important factor may be the presence of a protected space where new bone tissue can develop and mature.

This is directly relevant to how engineers think about the geometry and internal architecture of 3D-printed implants made from composites in the broader ResorBone™ material class. The design of the implant itself, not only its chemical composition, may influence how actively the material environment supports new bone formation.

The material tested in this study was not ResorBone™ and the researchers did not evaluate biodrook products. It was a specially developed extruded PLA/HA composite with a 50/50 composition.

Direct testing of biodrook products in comparable animal models would therefore represent a separate future research step.

Nevertheless, this work expands the scientific evidence surrounding resorbable polyester-hydroxyapatite composites. It suggests that, under appropriately engineered conditions, such materials may do more than simply provide a passive surface for bone growth and may have the potential to contribute actively to the initiation of new bone formation.

This article is a popular science review of a published study and does not constitute an advertising claim regarding the properties of a specific medical device. The conformity and clinical performance of biodrook implants are supported by the manufacturer’s own documentation.

Source: Danoux CB, Barbieri D, Yuan H, de Bruijn JD, van Blitterswijk CA, Habibovic P. In vitro and in vivo bioactivity assessment of a polylactic acid/hydroxyapatite composite for bone regeneration. Biomatter. 2014;4:e27664. doi:10.4161/biom.27664

CONTACT US

info@biodrook.com

Start building the future of accessible biotechnology with biodrook today!